Blood Journal
Leading the way in experimental and clinical research in hematology

CD molecules 2005: human cell differentiation molecules

  1. Heddy Zola,
  2. Bernadette Swart,
  3. Ian Nicholson,
  4. Bent Aasted,
  5. Armand Bensussan,
  6. Laurence Boumsell,
  7. Chris Buckley,
  8. Georgina Clark,
  9. Karel Drbal,
  10. Pablo Engel,
  11. Derek Hart,
  12. Václav Horejsí,
  13. Clare Isacke,
  14. Peter Macardle,
  15. Fabio Malavasi,
  16. David Mason,
  17. Daniel Olive,
  18. Armin Saalmueller,
  19. Stuart F. Schlossman,
  20. Reinhard Schwartz-Albiez,
  21. Paul Simmons,
  22. Thomas F. Tedder,
  23. Mariagrazia Uguccioni, and
  24. Hilary Warren
  1. From the Child Health Research Institute, North Adelaide, South Australia, Australia; the Immunology Laboratory, Department of Veterinary Patobiology, Royal Veterinary and Agriculture University, Stigbojlen, Denmark; the Faculte de Medicine de Creteil INSERM 448, Creteil Cedex, France; the Department of Rheumatology, Division of Immunity and Infection, MRC Centre for Immune Regulation, University of Birmingham, Edgbaston, United Kingdom; the Mater Medical Research Institute, Aubigny Place, Mater Hospital, Queensland, Australia; the Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic; the Immunology Department, Cellular Biology and Pathology Medical School, University of Barcelona, Spain; the Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, United Kingdom; the Department of Immunology, Flinders Medical Centre, Bedford Park, South Australia, Australia; the Immunogenetics Laboratory, University of Torino Medical School, Torino, Italy; the Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom; the Faculté de Médecine de Marseille and Centre Lutte Contre le Cancer, Laboratoire d'Immunologie des Tumeurs, Université de la Méditerranée, Marseille, France; the Klinische Immunologie, Klinisches Department für diagnostische Verfahren, Veterinärmedizinische Universität Wien, Wien, Austria; the Dana-Farber Cancer Institute, Boston, MA; the German Cancer Research Center, Tumor Immunology Laboratory, Heidelberg, Germany; the Stem Cell Research Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; the Department of Immunology, Duke University Medical Center, Durham, NC; the Institute for Research in Biomedicine, Bellinzona, Switzerland; and the Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, New South Wales, Australia.

Abstract

The immune system works through leukocytes interacting with each other, with other cells, with tissue matrices, with infectious agents, and with other antigens. These interactions are mediated by cell-surface glycoproteins and glycolipids. Antibodies against these leukocyte molecules have provided powerful tools for analysis of their structure, function, and distribution. Antibodies have been used widely in hematology, immunology, and pathology, and in research, diagnosis, and therapy. The associated CD nomenclature is commonly used when referring to leukocyte surface molecules and antibodies against them. It provides an essential classification for diagnostic and therapeutic purposes. The most recent (8th) Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA), held in Adelaide, Australia, in December 2004, allocated 95 new CD designations and made radical changes to its aims and future operational strategy in order to maintain its relevance to modern human biology and clinical practice.

  • Submitted April 4, 2005.
  • Accepted June 30, 2005.
View Full Text